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ABSTRACT
ObjeCtives
To examine the effectiveness of primary implantable 
cardioverter defibrillators (ICDs) in elderly patients 
receiving the device during a hospital admission for 
exacerbation of heart failure or other acute 
co-morbidities, with an emphasis on adjustment for 
early mortality and other factors reflecting healthy 
candidate bias rather than the effect of the ICD.
Design
Retrospective cohort study.
setting
Linked data from the Centers for Medicare and Medicaid 
Services and American College of Cardiology-National 
Cardiovascular Data Registry ICD registry, nationwide 
heart failure registry, and Medicare claims data 2004-09.
POPulatiOn
23 111 patients aged ≥66 who were admitted to 
hospital for exacerbation of heart failure or other acute 
co-morbidities and eligible for primary ICDs.
Main OutCOMe Measures
All cause mortality and sudden cardiac death. Latency 
analyses with Cox regression were used to derive crude 
hazard ratios and hazard ratios adjusted for high 
dimension propensity score for outcomes after 180 
days from index implantation or discharge.
results 
Patients who received an ICD during a hospital 
admission had lower crude mortality risk than patients 
who did not receive an ICD (40% v 60% at three years); 
however, with conditioning on 180 day survival and 
with adjustment for high dimension propensity score, 
the apparent benefit with ICD was no longer evident for 
sudden cardiac death (adjusted hazard ratio 0.95, 
95% confidence interval 0.78 to 1.17) and had a 
diminished impact on total mortality (0.91, 0.82 to 
1.00). There were trends towards a benefit with ICD in 
reducing mortality or sudden cardiac death in patients 
who had had a myocardial infarction more than 40 
days previously, left bundle branch block, or low serum 
B type natriuretic peptide; however, these trends did 
not reach significance.
COnClusiOn 
After adjustment for healthy candidate bias and 
confounding, the benefits of primary ICD therapy seen 
in pivotal trials were not apparent in patients aged 66 
or over who received ICDs during a hospital admission 
for exacerbation of heart failure or other acute 
co-morbidities. Future research is warranted to further 
identify subgroups of elderly patients who are more 
likely to benefit from ICDs. Recognition of those 
patients whose dominant risk factors are from 
decompensated heart failure and non-cardiac 
co-morbidities will allow better focus on ICDs in those 
patients for whom the device offers the most benefit 
and provides meaningful prolonging of life.
Introduction
The most recent worldwide survey of cardiac pacing 
and implantable cardioverter defibrillators (ICDs) 
from 2009 reported a large global rise in the use of 
these devices.1 The United States is the world’s largest 
consumer of ICDs, with 133 262 implants (or 434 new 
implants per one million people), which was 1.5 times 
the rate of the world’s second largest implanter.1 
Review of US nationwide data on ICD implantation 
has shown that real world recipients are typically 
older than patients in previous trials, with a median 
age of 74,2 similar to reports from other countries.3 As 
the  population ages, the number of elderly patients 
considered for ICD implantation worldwide will most 
likely increase.4 5
WhAT IS AlReAdy knoWn on ThIS TopIC
The benefit of primary implantable cardioverter defibrillators (ICDs) has been 
shown in outpatients with symptoms of stable mild-to-moderate heart failure
It is unclear how the impact of primary ICDs in preventing sudden cardiac death 
translates to overall survival benefits among elderly patients who receive the 
devices during acute admissions for exacerbation of heart failure or other acute 
co-morbidities
Evaluating survival benefits of ICDs in the real world setting without accounting for 
healthy candidate effect could overestimate its effectiveness
WhAT ThIS STudy AddS
This study used multiple analytical approaches (latency analysis and adjustment 
for high dimensional propensity scores) to account for healthy candidate bias in 
assessing effectiveness of ICDs with observational data
After adjustment for healthy candidate bias and confounding, the benefits of 
primary ICD therapy shown in previous trials were not present in elderly patients 
who received the device during admission for exacerbation of heart failure or other 
acute co-morbidities
The trend was similar in subgroups of patients aged under 80, in both sexes, and in 
racial subgroups
There was a trend towards benefit in reducing mortality or sudden cardiac death in 
patients who had had a myocardial infarction more than 40 days previously, left 
bundle branch block, or low serum B type natriuretic peptide
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The benefit of primary ICD therapy in landmark trials 
was shown in patients with heart failure in their 60s.6 7 
The results from these trials, however, might not 
directly apply to older populations. Real world recipi-
ents of ICDs generally have more non-cardiac co-mor-
bidities.2 8 Furthermore, primary ICD trials were 
conducted in outpatients with symptoms of stable 
mild-to-moderate heart failure.6 7  About a third of older 
recipients of ICDs have undergone an implantation 
during a hospital admission for exacerbation of heart 
failure or other acute co-morbidities.9  In patients with 
chronic heart failure, the early post-discharge period 
after an acute admission is associated with a high risk 
of mortality, during which progressive heart failure is 
the most likely cause of death.10 It is therefore unclear 
how the impact of primary ICDs on the prevention of 
sudden cardiac death translates to overall survival ben-
efits among elderly patients who received the devices 
during acute admissions.
We examined the effectiveness of ICDs outside the 
previously studied populations in ICD trials. Our target 
population was elderly patients who received the device 
during acute admissions for exacerbation of heart fail-
ure or other acute co-morbidities. Assessment of the 
potential impact on survival with real world data 
requires caution because of healthy candidate bias. 
This type of selection bias could arise when patients at 
high risk of complications or deemed to be too sick to 
benefit are not selected for an ICD, and when patients 
are less interested in preventing sudden death because 
of the existing burden of other chronic illness. Evalua-
tion of the clinical effectiveness of ICDs without consid-
eration of the healthy candidate effect could 
overestimate its benefit.11  We therefore used specific 
design and analytic approaches to account for this bias 
when assessing the clinical effectiveness of ICDs 
implanted during admission for exacerbation of heart 
failure or other acute causes among elderly patients 
and potential differences in the effectiveness of ICDs by 
demographic and clinical characteristics. This included 
adjustment for mortality during the first 180 days, a 
period during which previous trials have shown no ben-
efit of ICDs.6 7
Methods
Data sources
We conducted a retrospective cohort study using the 
ICD registry of the Centers for Medicare and Medicaid 
Services (CMS) (2005-08); ICD registry of the American 
College of Cardiology-National Cardiovascular Data 
Registry (ACC-NCDR) (2005-08); a nationwide heart fail-
ure registry aggregated from several quality improve-
ment and accreditation programs, including the 
American Heart Association’s Get With the Guidelines 
program (2005-08); and Medicare institutional and 
non-institutional claims (2004-09).
ACC-NCDR and CMS-ICD registry
The Medicare/Medicaid ICD registry is a subset of the 
American College of Cardiology-National Cardiov-
ascular Data Registry’s ICD registry, which is the sole 
 repository for data on ICD implantation for Medicare 
beneficiaries.2 12-14 Hospital personnel enter data on the 
registry under routine quality control review.15 The reg-
istry includes information on patient history, clinical 
characteristics, drugs, facility information, provider 
information, indications for ICD, device information, 
and inpatient complications.
Heart failure registry
The data from the national clinical registries for 
patients with heart failure were aggregated from sev-
eral quality improvement and accreditation programs 
managed by Outcome Sciences using common data 
elements, data clarification procedures, and quality 
assurance practices. The aggregate database includes 
data from over 800 US hospitals in 50 states with 
close to 300 000 patients with a primary diagnosis of 
heart failure. The dataset has been successfully used 
to assess quality of care outcomes in patients with 
heart failure.16  17 Information in the registry includes 
demographics, characteristics of heart failure, car-
diac and non-cardiac medical history, laboratory 
data, vital signs, findings on relevant physical exam-
inations, drugs on admission and at discharge, and 
other relevant treatment/procedures before and 
during admission.
Medicare institutional and non-institutional files
Medicare is the national health insurance program 
administrated by the US government. Most of its bene-
ficiaries are aged 65 or older. The Medicare institutional 
and non-institutional files contain data on final claims 
submitted by healthcare providers. Main information 
contained in those files includes diagnosis and proce-
dures, dates of service, reimbursement amount, pro-
vider identifiers, and demographic information on 
beneficiaries. Appendix 1 provides more details of these 
data sources.
Data linkage
We linked the combined ICD registry and the heart 
failure registry to Medicare claims data using four 
non-unique identifiers: date of birth, sex, admission 
date for implantation of the ICD, and provider identifi-
ers, which is described in detail elsewhere18  and in 
appendix 1. Briefly, we validated this linkage among 
the subset of 196 923 patients who had a unique iden-
tifier in the ICD registry. Our linkage using non-unique 
identifiers yielded 98% specificity, 95% sensitivity, 
and a 98% positive predictive value compared with the 
linkage method using both non-unique and unique 
identifiers.18
study population
Our study population consisted of elderly patients 
with heart failure with and without ICDs who had 
acute hospital admissions for heart failure or any 
co-morbidities and were considered eligible for ICD 
therapy for  primary prevention. The primary cohort 
consisted of older patients who were covered by Medi-
care and who could be linked to either the ICD or heart 
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failure registry. The secondary cohort consisted of 
older patients who were nested within the heart fail-
ure registry linked to Medicare data. To ensure their 
eligibility for primary ICD therapy, all study patients 
were required to have an ejection fraction of ≤35% at 
the time of admission. We excluded patients with car-
diac arrest or sustained ventricular tachycardia, for 
whom ICDs would be secondary prevention. To ensure 
our study patients had a sufficient look-back period for 
assessing pertinent covariates, we required that 
patients had health insurance coverage for one year 
before the index procedure or admission. We also 
required patients to be aged ≥66 to ensure everyone 
had a one year look-back period. The exposure status 
(ICD implantation) was defined as a patient having a 
record of ICD implantation in the ICD registry. Lastly, 
we excluded patients who received cardiac resynchro-
nization therapy with a defibrillator (CRT-D) as these 
patients met additional criteria for this indication.19-21 
The information on the type of implanted device was 
obtained from the ICD registry.
Outcomes
Our primary outcome was all cause mortality. The date 
of death was obtained from the Medicare beneficiary 
summary file. The secondary outcome was sudden car-
diac death, defined by using a previously validated 
algorithm (positive predictive value 87%).22  The desig-
nation of sudden cardiac death was made if the patient 
was not staying at a terminal institution (that is, hospi-
tal or nursing home) on the date of death, their code for 
underlying cause of death was consistent with sudden 
cardiac death (see appendix 2), and they did not have a 
“terminal procedure inconsistent with unresuscitated 
cardiac arrest, such as radiology, thrombolysis or gen-
eral anesthetic.”22  The cause of death was obtained 
from the National Death Index23 (appendix 3). We 
obtained index data on all the patients with an ICD and 
a randomly selected sample (70%) of those without in 
the primary cohort.
Latency analyses
We used latency analysis to adjust for potential healthy 
candidate bias, analogous to the healthy worker 
effect.24-26  Follow-up began after a prespecified latent 
period after the index date. In the current study, the 
index date was the date of implantation for the ICD 
group or the date of discharge for those without an ICD. 
As previous trials have shown that survival benefits of 
ICDs are not apparent until 1-1.5 years after implanta-
tion,6 7 we used latency periods of 180 days (primary 
latency period) and 365 days (secondary latency 
period). All patients were followed until the occurrence 
of an outcome event (death or sudden cardiac death) or 
the end of the study period (31 December 2009).
Statistical analyses
Patient characteristics were described as percentages 
for categorical variables by ICD exposure status. 
 Medians and interquartile ranges or means and stan-
dard deviations were used for continuous variables. 
We plotted observed mortality by ICD exposure status 
using Kaplan-Meier estimates. Cox regression was 
used to derive crude hazard ratios and hazard ratios 
adjusted for high dimensional propensity score for 
outcomes using the groups without an ICD (that is, 
older people admitted with equivalent indication for 
a primary ICD but who did not receive an ICD) as a 
reference.
We used the high dimensional propensity score 
methods to adjust for surrogates of unmeasured fac-
tors to overcome residual confounding. The algorithm 
was used to thoroughly screen Medicare claims data 
to identify covariates that could collectively be surro-
gates for unobserved factors influencing the patient 
selection for ICDs.27  This allows for maximum control 
of potential confounders given the available informa-
tion in our data sources. For example, although we 
did not have information on NYHA class for heart fail-
ure, we can adjust for this based on other available 
proxies for severity of heart failure in the dataset, 
including numbers of previous hospital admissions 
for heart failure, ejection  fraction, blood pressure, 
B type natriuretic peptide, or co-morbidities. To cal-
culate high dimensional propensity scores, we used 
data from the year before the index date. The 200 
most common codes in each data dimension were 
identified, from which 500 likely confounders were 
selected based on their prevalence and potential for 
confounding in the study population. The scores at 
the index date were derived from predicted probabili-
ties from logistic regression models containing all of 
the empirically identified covariates and several pre-
defined variables: demographic characteristics; cause 
of index admission, admission source, admission 
type, and diagnostic/laboratory test results for ejec-
tion fraction, systolic blood pressure, serum sodium, 
serum B type natriuretic peptide, and estimated 
 glomerular filtration rate.28
We handled variables with missing values (such as 
systolic blood pressure, serum sodium, B type natri-
uretic peptide, and creatinine) by multiple imputa-
tion29 and assumed an underlying multivariate 
normal distribution. Our analysis was based on five 
imputed datasets in which the imputation model 
included all variables in the outcome model (ICD use 
outcomes and potential confounders) as well as vari-
ables related to missingness (see appendix 4 for 
potential predictors of missing values included in the 
imputation model). We repeated all analyses in the 
secondary cohort.
Subgroup analyses
We assessed the heterogeneity of the effects of ICD by 
demographic characteristics (age, sex, and race) and 
three clinical characteristics (history of myocardial 
infarction,30 31 presence of left bundle branch 
block,32 33 and type natriuretic peptide concentration 
at index admission) using separate Cox models in 
each  subgroup.
Age was categorized in four groups in five year 
increments. We used a previously validated claim 
doi1 02.00;6/bmj.h;1 29 | BMJ   2015;101h;1 29 | the bmj
RESEARCH
4
based definition to identify myocardial infarction34 
and classified this population into three groups: 
recent myocardial infarction (one or more myocardial 
infarctions within the 40 days before the index date), 
old myocardial infarction (one or more myocardial 
infarctions 41-365 days before the index date), and no 
myocardial infarction within 365 days before the 
index admission. We also used a claim based defini-
tion to identify patients with left bundle branch block 
within 365 days before the index date (ICD-9 (interna-
tional classification of diseases, ninth revision, clini-
cal modification), 426.2x or 426.3x). We required the 
diagnosis of left bundle branch block to be made 
during a hospital admission. We classified our 
patients into two groups according to B type natri-
uretic peptide concentration (low v high) using a cut-
off value of 800 ng/L.35-37
We adjusted for potential confounding using the high 
dimensional propensity score estimated from the entire 
cohort.38
Sensitivity analyses
We repeated all analyses in a subset of the population 
with complete laboratory data and a subset of the pop-
ulation matched on high dimensional propensity score 
(that is, the high dimensional propensity score matched 
analyses). This was done to assess the impact of the 
missing data assumption on our findings and the 
robustness of the adjustment using the  high dimen-
sional propensity score.
All analyses were conducted with SAS 9.2 (SAS Insti-
tute, Cary, NC).
Results
study population and characteristics
We identified a cohort of 23 111 patients with heart 
failure (5258 with an ICD and 17 853 without) who met 
eligibility criteria (figs 1  and 2 ). For over 90% of the 
patients, the diagnosis that led to the index admis-
sion was heart failure or other cardiac causes. 
Patients with ICDs were younger and were more likely 
to be men than patients without ICDs. They also had a 
lower ejection fraction, more previous admissions for 
cardiac diseases, and more physician visits, and their 
heart failure was more likely to have an ischemic 
cause. Patients with ICDs also had a higher preva-
lence of non-cardiac admissions, chronic kidney dis-
ease, metastatic cancer, lower  estimated glomerular 
filtration rate, and higher B type natriuretic peptide 
(table1). These findings were similar in the secondary 
cohort (appendix 5).
ICD implantations among patients
aged ≥66 at admission, 2005-08 (n=211 229)
Records with complete information
on linkage variables (n=196 923)
Records linked to Medicare fee for
service inpatient records (n=118 047)
Patients with low ejection fraction
and rst primary ICD (n=70 417)
Information on cause of death requested for 100% of population
Primary ICD recipients eligible for analyses (n=5258)
Excluded:
  Previous cardiac arrest (n=17 923)
  History of sustained VT (n=2443)
  <1 year continuous eligibility before ICD implant
    (n=3282)
  No claim indicating ICD implantation (n=145)
  CRT-D recipients (n=35 711)
  Patients received ICD implantation during elective
    hospital admission (n=12 630)
Records with missing or invalid linkage variables
– that is, admission date, provider ID,
date of birth, and sex (n=14 306, 6.8%)
Excluded:
  Missing ejection fraction (n=3297)
  Ejection fraction >35% (n=13 367)
  Secondary prevention (n=35 872)
  Repeated ICD implantation (n=1858)
Fig 1 | identification of study population of patients 
with heart failure with implantable cardioverter 
defibrillator (iCD)
Admissions for heart failure among patients
aged ≥66 at admission, 2005-08 (n=307 505)
Records with complete information and
valid on linkage variables (n=284 638)
Outcome registry records linked to Medicare
fee for service inpatient records (n=210 144)
Patients with low ejection fraction and admitted
for heart failure or comorbidities (n=43 891)
Information on cause of death
requested for about 70% of population
Patients with cause of death information
eligible for analyses (n=17 853)
Patients eligible for primary ICD therapy
but did not received ICDs (n=25 211)
Excluded:
  Previous ICD implantation (n=9096)
  ICD implantations during admission (n=1784)
  Record identied in ICD registry (n=4504)
  Previous cardiac arrest in registry (n=8107)
  History of sustained VT (n=418)
  <1 year continuous eligibility before index
    admission (n=2622)
Records with suspicious value or missing value on
linkage variable – that is, admission date, date of birth,
or discharge date, provider state (n=22 867, 7.2%)
Excluded:
  Missing ejection fraction (n=58 820)
  Ejection fraction >35% (n=104 258)
Fig 2 | identification of study population of patients 
with heart failure without implantable cardioverter 
defibrillator (iCD)
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Crude mortality risks and Kaplan-Meier curves
During follow-up (average 2.8 years, range 1 day-5 
years), 12 293 (53%) patients died. The crude mortality 
risk among our Medicare population admitted to the 
hospital was 34% (95% confidence interval 33% to 35%) 
at one year and 56% (55% to 57%) at three years. The 
mortality curves for the patients with and without ICDs 
(fig 3) began to diverge immediately after ICD implanta-
tion (2.4% (2.0% to 2.8%) v 12.7% (12% to 13%) at 30 
days). Crude mortality at one year was lower for ICD 
recipients than for eligible patients without an ICD 
(18% (17% to 19%) v 39% (38% to 40%) at one year and 
40% (38% to 41%) v 60% (60% to 61%) at three years). 
However, the crude mortality in these hospitalized 
Medicare patients with an ICD at one year was similar to 
the mortality seen at three years in trials of ICDs in 
ambulatory recipients.6 7
effectiveness of iCDs 
After adjustment for bias with latency analyses and the 
high dimension propensity score, patients who received 
an ICD during an acute admission for heart failure or 
other co-morbidity did not have a substantially differ-
ent risk of mortality (hazard ratio 0.91, 95% confidence 
interval 0.82 to 1.00) or sudden cardiac death (0.95, 0.78 
to 1.17) than those who had no ICD during their admis-
sion (table 2 , fig 4 ). This trend remained when we 
extended the latency period to 365 days (table 2 ) and 
when the analyses were restricted to the smaller sec-
ondary cohort (table 2 , fig 4 ). This trend was also simi-
lar in the sensitivity analyses (table 3).
effectiveness of iCDs in demographic subgroups
The proportion of eligible patients who received ICDs 
varied among demographic subgroups with notable dif-
ferences in age and sex. Women and the oldest patients 
made up smaller fractions of recipients of ICDs: 14% 
women versus 29% men, and 12% in the ≥81 age group 
versus 28-34% in other age groups (table 4 ). This 
 suggests that ICD implantation might have been more 
selective among these groups. We found no significant 
differences in ICD effectiveness among most 
 demographic subgroups, except in the small group of 
patients aged over 81. Among these older patients, ICD 
use was associated with a lower mortality risk (hazard 
ratio 0.78, 95% confidence interval 0.65 to 0.93) but not 
with a significant reduction in risk of sudden cardiac 
death (0.74, 0.52 to 1.04; fig 5 , table 4 ). The trend was 
similar when we extended the latency period to 365 
days (table 4).
effectiveness of iCDs in clinical subgroups
Effectiveness by myocardial infarction status
The findings in the subgroups with and without recent 
myocardial infarction showed similar effectiveness of 
ICDs (table 5). Among patients with an old myocardial 
infarction, ICD therapy was associated with a signifi-
cantly lower risk of mortality (37% reduction, hazard 
ratio 0.63, 95% confidence interval 0.45 to 0.86) and a 
table 1 | Main baseline characteristics of patients aged ≥66 with heart failure by 
exposure status (use of implantable cardioverter defibrillator (iCD)) in primary cohort. 
Figures are numbers (percentage) of patients unless stated otherwise
no iCD (n=17 853) iCD (n=5258) P value
Mean (SD) age (years) 80.0 (7.8) 75.5 (6.0) <0.001
Men 9321 (52) 3763 (72) <0.001
White 15 068 (84) 4392 (84) 0.13
Median (IQR) ejection fraction (%) 29 (20-33) 25 (20-30) <0.001
Median (IQR) Charlson scores 3 (1-4) 3 (1-4) 0.68
Patients with ≥1 hospital admission by cause:
 Any causes 9168 (51) 2912 (55) <0.001
 Heart failure 2844 (16) 1139 (22) <0.001
 Myocardial infarction (MI) 203 (1) 84 (2) 0.01
 Non-MI ischemic heart disease 104 (1) 74 (1) <0.001
 Other cardiac disease 51 (0) 39 (1) <0.001
 Non-cardiac causes 6501 (36) 1673 (32) <0.001
Mean (SD) No of prior outpatient visits 10.3 (9.4) 11.7 (9.3) <0.001
≥1 prior outpatient visit 16 167 (91) 4974 (95) <0.001
≥1 prior skilled nursing facility admission 2679 (15) 375 (7) <0.001
Heart failure due to ischemic causes 14 165 (79) 4587 (87) <0.001
Any cerebrovascular disease 3860 (22) 1224 (23) 0.01
Hemorrhagic stroke 198 (1) 93 (2) <0.001
Ischemic stroke 1376 (8) 462 (9) 0.01
Transient ischemic attack 1175 (7) 424 (8) <0.001
Other cerebrovascular disease 2741 (15) 816 (16) 0.78
Peripheral vascular disease 4147 (23) 1279 (24) 0.10
Dementia 3503 (20) 584 (11) <0.001
Depression 2821 (16) 662 (13) <0.001
Any liver disease 1118 (6) 323 (6) 0.77
Gastrointestinal ulcer/bleeding 2755 (15) 736 (14) 0.01
Dialysis 527 (3) 151 (3) 0.78
Chronic kidney disease 8009 (45) 2201 (42) <0.001
Chronic obstructive pulmonary disease 8283 (46) 2436 (46) 0.93
Cancer (except non-melanoma skin cancer) 3020 (17) 898 (17) 0.79
Metastatic cancer 566 (3) 100 (2) <0.001
Diabetes 8648 (48) 2800 (53) <0.001
Median (IQR) systolic blood pressure (SBP) 133 (116-152) 130 (115-146) <0.001
 SBP missing 9230 (52) 70 (1) —
Median (IQR) serum sodium 138 (136-141) 138 (136-140) 0.004
 Sodium missing 12 032 (67) 29 (1) —
Median (IQR) serum B type natriuretic 
peptide (BNP)
1249 (657-2258) 760 (336-1590) <0.001
 BNP missing 12 810 (72) 3167 (60) —
Median (IQR) serum creatinine (SCr) 1.3 (1.0-1.8) 1.2 (1.0-1.6) <0.001
 SCr missing 11 488 (64) 22 (0) —
Median (IQR) estimated glomerular filtration rate 47 (32-64) 56 (41-72) <0.001
IQR=interquartile range
Years since index time
Cr
ud
e 
m
or
ta
lit
y
0 1 2 3 4 5
0
0.2
0.4
0.6
0.8
1.0
Non-ICD group (n=17 853)
ICD group (n=5258)
Fig 3 | Crude mortality curves for patients with heart failure 
with (n=5258) and without implantable cardioverter 
defibrillator (iCD) (n=17 853) in primary cohort
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non-significant 26% reduction in sudden cardiac death 
(0.74, 0.40 to 1.35).
Effectiveness by presence of left bundle branch block
ICD use was associated with a lower risk of mortality 
(hazard ratio 0.64, 95% confidence interval 0.34 to 1.17) 
and sudden cardiac death (0.51, 0.16 to 1.61) among 
patients with left bundle branch block (table 5); 
although the confidence intervals were wide.
Effectiveness by serum B type natriuretic peptide 
status
A total of 7134 patients had their admission serum B 
type natriuretic peptide value documented (2091 (40%) 
patients with ICD v 5043 (28%) without). Risks of mor-
tality and sudden cardiac death associated with ICD 
therapy were numerically lower among patients with 
low serum B type natriuretic peptide (hazard ratios 0.86 
(95% confidence interval 0.67 to 1.10) for mortality and 
1.11 (0.69 to 1.77) for sudden cardiac death) than those 
with high type natriuretic peptide (0.94 (0.78 to 1.13) 
and 1.20 (0.85 to 1.69), respectively); however, these risk 
estimates were not significant (table 5).
discussion
Main findings
The benefits of primary ICD therapy that had been 
previously shown in ambulatory patients with heart 
failure do not seem to translate to elderly patients 
who receive the device during acute hospital admis-
sions for exacerbation of heart failure or other acute 
co-morbidities. Adjustment for potential confounding 
and healthy candidate bias11 in this specific popula-
tion reduced the apparent impact of ICD therapy to a 
5% reduction in sudden cardiac death and a 9% 
reduction in all cause mortality, which were not sig-
nificant. This trend remained similar among sub-
groups of patients aged under 80 and across the sexes 
and racial subgroups. There was, however, a trend 
towards benefit of ICDs implanted during acute 
admissions to hospital in reducing mortality or sud-
den cardiac death in patients who had non-recent 
myocardial infarction more than 40 days prior to 
implantation, left bundle branch block, or lower 
serum B type natriuretic peptide, although these also 
did not reach significance.
strength and limitations
Our study is the first to use latency analysis to account 
for the healthy candidate bias in assessing effectiveness 
table 2 | number of events and incidence rates for death and sudden cardiac death in patients with and without implantable cardioverter defibrillator 
(iCD) in latency 180 day* and latency 365 day* analyses
group
Death sudden cardiac death
event/ir†
Hr (95% Ci)
event/ir†
Hr (95% Ci)
Crude adjusted‡ Crude adjusted
latency 180 day
Primary cohort
 ICD (n=5258) 1307/159 0.69 (0.65 to 0.74) 0.91 (0.82 to 1.00) 330/40 0.71 (0.62 to 0.82) 0.95 (0.78 to 1.17)
 No ICD (n=17 853) 5299/241 Reference Reference 1326/60 Reference Reference
Secondary cohort
 ICD (n=412) 125/201 0.90 (0.71 to 1.14) 1.01 (0.79 to 1.29) 40/64 1.26 (0.82 to 1.93) 1.20 (0.71 to 2.00)
 No ICD (n=17 853) 5299/241 Reference Reference 1326/60 Reference Reference
latency 365 day
Primary cohort
 ICD (n=5258) 925/155 0.73 (0.68 to 0.79) 0.94 (0.83 to 1.06) 234/39 0.75 (0.65 to 0.87) 0.96 (0.76 to 1.21)
 No ICD (n=17 853) 3524/220 Reference Reference 880/55 Reference Reference
Secondary cohort
 ICD (n=412) 90/203 0.95 (0.72 to 1.27) 1.02 (0.72 to 1.43) 28/63 1.13 (0.67 to 1.90) 0.94 (0.49 to 1.80)
 No ICD (n=17 853) 3524/220 Reference Reference 880/55 Reference Reference
All cause mortality
  Primary cohort
  Secondary cohort
Sudden cardiac death
  Primary cohort
  Secondary cohort
0.91 (0.82 to 1.00)
1.01 (0.79 to 1.29)
0.95 (0.78 to 1.17)
1.20 (0.71 to 2.00)
0.5 0.8 1 2
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Fig 4 | Hazard ratios (adjusted for high dimension 
propensity score) for death and sudden cardiac death 
among primary and secondary cohorts in latency 180 day 
analyses
table 3 | Primary and sensitivity analyses of iCD effectiveness. Figures are hazard ratios (95% Ci) adjusted for high dimension propensity score 
(hdPs)*Complete case analyses not conducted in secondary cohort because of smaller size of cohort.
Primary cohort secondary cohort
iCD/no iCD Death sudden cardiac death iCD/no iCD Death
sudden cardiac 
death
Primary analyses 5258/17 853 0.91 (0.82 to 1.00) 0.95 (0.78 to 1.17) 412/17 853 1.01 (0.79 to 1.29) 1.20 (0.71 to 2.00)
hdPS matched analyses 2254/2254 0.92 (0.77 to 1.09) 1.03 (0.78 to 1.35) 291/291 0.99 (0.72 to 1.37) 1.50 (0.94 to 2.38)
Complete case analyses 1801/3261 0.87 (0.72 to 1.05) 1.15 (0.79 to 1.66) —* —* —*
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of ICDs with observational data. Several lines of 
 evidence suggest the existence of healthy candidate 
bias in the observational studies of ICD. Although the 
mortality curves of previous randomized trials show 
no ICD benefit until 1-1.5 years,6 7  we observed an 
immediate separation of the mortality curves in both 
our current and previous study,11  which is probably 
caused by healthy candidate bias due to selection of 
patients for ICD rather than immediate ICD benefit. 
The existence of healthy candidate bias among 
patients in hospital has been supported by evidence 
that ICD recipients had a 40-50% lower risk of adverse 
events, such as non-traumatic hip fracture and admis-
sion to a skilled nursing facility, than similar patients 
who did not receive an ICD.11  This bias in patient and 
physician selection for ICD implantation cannot be 
completely eliminated by adjustment for known risk 
factors and can lead to overestimation of the net bene-
fit of ICDs.11 The disparity between groups is further 
suggested by a greater difference in total mortality 
(including non-cardiac death) than in sudden cardiac 
death, which is the only event that is expected to be 
reduced by ICDs.
Among strategies that have been developed to 
account for healthy candidate bias, latency analysis has 
been shown to be useful25  and is suitable to evaluate 
ICD effectiveness because of the delayed benefit seen in 
trials.6 7  This method allows a less biased evaluation by 
focusing on a time period more likely to reflect true ICD 
table 4 | effectiveness of implantable cardioverter defibrillators (iCDs) in demographic subgroups in latency 180 day* and latency 365 day* analyses
sample size  
(iCD/no iCD)
% of eligible patients 
received iCD event (iCD/no iCD) ir† (iCD/no iCD)
adjusted Hr (95% Ci)‡
latency 180 day latency 365 day
Outcome=death
Age (years):
 66-70 1322/2534 34 285/568 127/137 0.89 (0.70 to 1.13) 1.02 (0.77 to 1.36)
 71-75 1347/2950 31 301/755 136/168 1.11 (0.88 to 1.40) 1.33 (1.02 to 1.74)
 76-80 1394/3670 28 362/1068 172/216 0.92 (0.75 to 1.12) 0.82 (0.65 to 1.04)
 ≥81 1195/8699 12 359/2908 213/345 0.78§ (0.65 to 0.93) 0.78§ (0.63 to 0.96)
Sex:
 Men 3763/9321 29 945/2779 161/245 0.92 (0.81 to 1.04) 0.96 (0.82 to 1.11)
 Women 1495/8532 14 362/2520 152/237 0.90 (0.75 to 1.07) 0.90 (0.74 to 1.10)
Race:
 White 4392/15 068 23 1088/4402 156/241 0.90 (0.81 to 1.01) 0.96 (0.84 to 1.10)
 Black 613/1790 26 154/594 172/240 0.93 (0.70 to 1.24) 0.82 (0.57 to 1.16)
 Other 253/995 20 65/303 181/240 0.94 (0.60 to 1.47) 0.84 (0.50 to 1.39)
Outcome=sudden cardiac death
Age (years):
 66-70 1322/2534 34 73/125 33/30 1.04 (0.63 to 1.72) 1.12 (0.62 to 2.00)
 71-75 1347/2950 31 59/176 27/39 0.81 (0.48 to 1.35) 0.73 (0.41 to 1.27)
 76-80 1394/3670 28 99/215 47/44 1.43 (0.95 to 2.14) 1.30 (0.82 to 2.07)
 ≥81 1195/8699 12 99/810 59/96 0.74 (0.52 to 1.04) 0.80 (0.54 to 1.18)
Sex:
 Men 3763/9321 29 248/732 42/65 1.00 (0.78 to 1.28) 1.08 (0.82 to 1.42)
 Women 1495/8532 14 82/594 35/56 0.86 (0.59 to 1.26) 0.75 (0.50 to 1.15)
Race:
 White 4392/15 068 23 288/1121 41/61 0.98 (0.79 to 1.23) 1.06 (0.82 to 1.36)
 Black 613/1790 26 31/135 35/54 0.77 (0.40 to 1.47) 0.44 (0.20 to 1.00)
 Other 253/995 20 11/70 31/55 0.75 (0.24 to 2.33) 0.60 (0.16 to 2.22)
*Latency 180 day analyses: starting follow-up from 180 days after index time; latency 365 day analyses: starting follow-up from 365 days after index time
†IR=incidence rate per 1000 person years.
‡Adjusted for high dimension propensity score.
§P<0.05.
Death
  Age (years):
    66-70
 71-75
 76-80
 ≥81
  Men
  Women
  Ethnicity:
    White
 Black
 Other
Sudden cardiac death
  Age (years):
    66-70
 71-75
 76-80
 ≥81
  Men
  Women
  Ethnicity:
    White
 Black
 Other
0.89 (0.70 to 1.13)
1.11 (0.88 to 1.40)
0.92 (0.75 to 1.12)
0.78 (0.65 to 0.93)
0.92 (0.81 to 1.04)
0.90 (0.75 to 1.07)
0.90 (0.81 to 1.01)
0.93 (0.70 to 1.24)
0.94 (0.60 to 1.47)
1.04 (0.63 to 1.72)
0.81 (0.48 to 1.35)
1.43 (0.95 to 2.14)
0.74 (0.52 to 1.04)
1.00 (0.78 to 1.28)
0.86 (0.59 to 1.26)
 
0.98 (0.79 to 1.23)
0.77 (0.40 to 1.47)
0.75 (0.24 to 2.33)
0.2 0.5 21 4
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Fig 5 | Hazard ratios (adjusted for high dimension 
propensity score) for death and sudden cardiac death 
among demographic subgroups in latency 180 day analyses
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effectiveness rather than preferential selection of ICDs 
for and by healthier patients. A few caveats should be 
noted. Healthy candidate bias can continue to influence 
outcomes beyond the initial chosen latency period, 
which is likely given our conservative 180 day latency 
period. Therefore, our latency analysis might still over-
estimate ICD survival benefit. Additionally, latency 
analyses could underestimate the survival benefit of 
ICDs if lifesaving events occurred more frequently 
during the prespecified latency period. Nevertheless, 
trial data have indicated such an underestimation is 
likely minimal.6 7
Several limitations need to be considered when our 
findings are interpreted. First, and foremost, our find-
ings are not applicable to elderly patients who would 
undergo ICD implantation electively as outpatients. 
Our study population was limited to elderly patients 
who received ICDs during acute admissions to hospital 
for reasons other than ICD implantation. We selected 
this population for analysis of effectiveness, as in a 
previous study by Hernandez and colleagues,39 
because data are available for comparison of similar 
patients admitted with heart failure who did not 
receive ICDs. Many elderly patients, however, receive 
the device as an elective procedure. The effectiveness 
of ICD among these healthier patients is more likely to 
be comparable with that of the trials on which the 
guideline  recommendations are based. Additionally, 
our findings cannot be generalized to patients who 
received cardiac resynchronization therapy with their 
ICD (CRT-D) as this is likely to decrease heart failure 
events. We also did not include patients who received 
the ICD as secondary prevention, for which lifesaving 
ICD therapies are more likely to occur.
We could not identify all patients with a history of 
myocardial infarction, left bundle branch block, or 
low serum B type natriuretic peptide values because 
we used a claims based definition and because of 
missing data on B type natriuretic peptide. Therefore, 
we did not have a sufficient sample size to confirm the 
trends seen for those subgroups thought to derive 
more benefit from ICDs.30-33 35  Neither did we have 
complete information on all the recognized risk fac-
tors for death from heart failure, such as the New York 
Heart Association class and duration of QRS. Residual 
confounding is possible. Regarding the general prob-
lem of missing values in registry variables, our results 
were robust to the missingness assumption, as the 
results based on imputed datasets were similar to 
complete case analyses.40
Comparison with other studies
Our study of patients admitted to hospital failed to 
show survival benefits of primary ICD therapy similar 
to those seen in trials of healthier ambulatory 
patients, in whom there was a 23-31% reduction in 
mortality6 7 ; this is likely explained by differences in 
the patient population. The median age of the SCD-
HeFT population was 60 and the mean age of the 
MADIT II population was 64.6 7  The patients in our 
study were older, with a mean age of 75 in the ICD 
recipients and 80 in those who did not receive an ICD. 
It is not clear that age alone is the major difference as 
benefit has been shown in subsets of elderly patients 
table 5 | effectiveness of implantable cardioverter defibrillators (iCDs) in clinical subgroups in latency 180 day* and latency 365 day* analyses
sample size  
(iCD/no iCD)
% of eligible patients 
received iCD event (iCD/no iCD) ir† (iCD/no iCD)
adjusted Hr (95% Ci)‡
latency 180 day latency 365 day
Outcome=death
Myocardial infarction:
 Recent 1685/8160 17 565/4476 165/333 0.92 (0.77 to 1.09) 0.94 (0.76 to 1.16)
 Old 448/904 33 186/648 226/532 0.63§ (0.45 to 0.86) 0.74 (0.51 to 1.08)
 No 3125/8789 26 1108/5317 172/369 0.90 (0.79 to 1.03) 0.91 (0.78 to 1.07)
Left bundle branch block:
 No 5143/17 406 23 1809/10 161 173/358 0.92 (0.83 to 1.01) 0.94 (0.83 to 1.06)
 Yes 115/447 20 50/280 213/401 0.64 (0.34 to 1.17) 0.75 (0.37 to 1.49)
B type natriuretic peptide:
 <800 1085/1604 40 359/905 157/302 0.86 (0.67 to 1.10) 0.86 (0.65 to 1.15)
 ≥800 1006/3439 23 490/2373 278/464 0.94 (0.78 to 1.13) 0.91 (0.72 to 1.13)
Outcome=sudden cardiac death
Myocardial infarction:
 Recent 1685/8160 17 115/542 34/40 1.03 (0.76 to 1.39) 0.92 (0.64 to 1.33)
 Old 448/904 33 27/83 33/68 0.74 (0.40 to 1.35) 1.12 (0.56 to 2.21)
 No 3125/8789 26 188/701 29/49 0.91 (0.70 to 1.18) 1.00 (0.73 to 1.38)
Left bundle branch block:
 No 5143/17 406 23 325/1289 31/45 0.97 (0.80 to 1.17) 1.02 (0.81 to 1.29)
 Yes 115/447 20 5/37 21/53 0.51 (0.16 to 1.61) 0.42 (0.09 to 2.05)
B type natriuretic peptide:
 <800 1085/1604 40 92/199 40/66 1.11 (0.69 to 1.77) 1.42 (0.82 to 2.46)
 ≥800 1006/3439 23 132/539 75/105 1.20 (0.85 to 1.69) 1.17 (0.76 to 1.80)
*Latency 180 day analyses: starting follow-up from 180 days after index time; latency 365 day analyses: starting follow-up from 365 days after index time.
†IR=incidence rate per 1000 person years.
‡Adjusted for high dimension propensity score.
§P<0.05.
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in randomized trials.41  More importantly, previous tri-
als were conducted among ambulatory patients with 
symptoms of stable mild-to-moderate heart failure, 
many of whom had not previously been admitted to 
hospital with heart failure. Our study focused on a 
population of patients admitted for exacerbation of 
heart failure or other acute causes. This particular 
subset of patients has a higher baseline burden of 
heart failure and other co-morbidities than trial pop-
ulations. Older age,42-44  advanced heart  failure,42 45 46 
and non-cardiac co-morbidities46 increase the likeli-
hood of mortality that will not be prevented by an 
ICD, and thus present competing risks for prolonged 
survival with an ICD.
Four previous studies reported that primary ICD 
implantation in routine clinical practice was associ-
ated with a sizable survival benefit comparable with 
those seen in major trials,39 47-49  but only one39 
included the subset of elderly patients who under-
went device implantation during an acute hospital 
admission. In addition, two of these studies enrolled 
participants from outpatient cardiology clinics, 
where the ICD was generally implanted as an elective 
procedure.48 49  The previous observational stud-
ies39 48 49 also found  immediate separation of survival 
curves at a point in time unlikely to be strongly influ-
enced by ICDs.
implications for practice and future research
Our results extend the understanding of the clinical 
effectiveness of ICDs in elderly patients admitted to 
hospital, who are not typical of patients in trials. 
Patients admitted for acute exacerbation of heart fail-
ure or other co-morbidities might be at greater risk 
both during ICD implantation and for non-arrhythmic 
events after discharge. For early risk, it is possible that 
there is some similarity between patients admitted for 
heart failure and patients early after myocardial infarc-
tion, who also showed no benefit from ICD and an 
increased risk of non-sudden cardiac death.30 31 50 For 
patients non-electively admitted to hospital for heart 
failure or their comorbidities, it might be appropriate 
to delay the decision to implant a primary ICD until 
they have been discharged and can be re-evaluated in 
the outpatient setting.
Our findings provide no reason to restrict access to 
ICDs for older patients with heart failure who other-
wise seem similar to patients in pivotal ICD trials. 
The subset of elderly patients who received primary 
prevention ICDs in trials in outpatient settings were 
previously shown to derive benefit.41 While an ideal 
study would be a randomized trial in elderly patients, 
this is not likely to be performed in time to inform 
imminent clinical decision making. We failed to 
show a benefit only for those older patients receiving 
ICDs during an urgent admission for exacerbation 
of heart failure or other acute causes. Future research 
is warranted to identify other groups of older 
patients who have a high or low likelihood of benefit 
from ICDs to maximize the lifesaving potential of 
their use.
The efficacy of ICDs in women has also been ques-
tioned, in large part because they were under-repre-
sented in previous trials.6 7 51  In our study of 10 027 
eligible women, we observed no heterogeneity in effec-
tiveness of ICDs between the sexes; however, it has 
been shown that female candidates for primary ICD are 
likely have a lower risk of sudden cardiac death than 
male candidates.52  Women also more often experience 
complications with ICDs.53 54 Thus, the benefit-risk 
equation of ICDs among women might require further 
investigation.
The higher survival associated with ICDs in patients 
aged over 81 further emphasizes the likelihood of resid-
ual bias that cannot be adjusted for using currently 
reported patient characteristics. The oldest group of 
patients in our study comprised the lowest proportion 
of ICD recipients out of eligible recipients. This proba-
bly indicates a particularly rigorous selection of healthy 
ICD recipients in this age group, excluding patients 
with obvious co-morbidities and more general frailty. 
Therefore, despite the use of latency analysis and 
adjustment for high dimension propensity scores, 
accounting for patient and physician selection is still 
challenging in assessing real world clinical 
 effectiveness.
Shared decision making regarding primary preven-
tion ICD has been recommended to involve explicit 
consideration of patient preferences and the likelihood 
of competing risks for mortality in all patients.55 These 
decisions require particular scrutiny for patients 
admitted to hospital for exacerbation of heart failure or 
other acute causes. Recognition of those patients 
whose dominant risks are from decompensated heart 
failure and non-cardiac co-morbidities will allow for 
focused ICD therapy in those patients for whom the 
device offers the most benefit to provide meaningful 
prolonging of life.
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